Month: April 2022
Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it is partnering with the European Society for Organ Transplantation…
Read More
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
SKYSCRAPER-02, the first randomized study of tiragolumab in extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival ES-SCLC is a hard-to-treat disease and Tecentriq plus chemotherapy remains a standard of care Tiragolumab continues to be evaluated in non-small cell lung cancer and other cancer types through additional Phase III…
Read More
– First therapeutic candidate for the treatment of SSc-ILD targeting both key fibrotic and inflammatory pathways – – ATHENA-SSc-ILD Phase 2 topline results expected first-half 2024 – – FDA has granted Fast Track Designation for PRA023 for the treatment of SSc-ILD – Excerpt from the Press Release: SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) —…
Read More
Demonstrates the Power of Cerevance’s Deep Understanding of Specific Human Brain Cell Types Excerpt from the Press Release: BOSTON, Mass., March 31, 2022 (GLOBE NEWSWIRE) — Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the completion of its Phase 2 clinical trial of CVN424, the company’s…
Read More
Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and expected to enroll up to approximately 80 patients NGM831 is the second of three programs comprising NGM Bio’s wholly-owned myeloid reprogramming and checkpoint inhibition portfolio to enter the clinic NGM831, NGM707…
Read More
– Preliminary data are expected in the second half of 2022 Excerpt from the Press Release: SAN DIEGO, March 24, 2022 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced the initiation of studies evaluating a library of oligonucleotides designed to…
Read More
Transfer of Trial Sponsorship Final Major Milestone before Initiation of Lung Failure Pivotal Clinical Trial Excerpt from the Press Release: CEANSIDE, Calif.–(BUSINESS WIRE)–Therapeutic Solutions International announced today the execution of a purchase agreement covering sponsorship and leadership of the FDA cleared Phase III pivotal trial assessing JadiCell adult stem cells for treatment of COVID-19 associated…
Read More
Excerpt from the Press Release: BOSTON, March 23, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the…
Read More
Results Demonstrated Anti-BCMA CAR T Cells Derived from Healthy Donors Had Better Immune Fitness and Killing Activity Phase 1 AlloCAR T™ Trials Underway Evaluating ALLO-715 and ALLO-605 for the Treatment of Relapsed/Refractory Multiple Myeloma BCMA Program Clinical Update Expected by the End of 2022 Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., March 23,…
Read More
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by Lightspeed Venture Partners. The company licensed its lead compound, KRLS-017, from Ube Industries, Ltd., a premier Japanese chemical manufacturer. The company also completed…
Read More